Application of an optimized and validated LC–MS/MS method for the quantification of free 3-nitrotyrosine in plasma, urine and liver tissue of lactating dairy cows

Barcarolo, D.; Angeli, Emmanuel; Ribas, Lucas E; Addona, Silvina M; Ortega, Hugo H.; Hein, Gustavo Juan

doi:10.1016/j.livsci.2022.104852

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3-Nitrotyrosine (3-NT) is a stable compound determined from cerebrospinal fluid, and AD patients also show increased levels. As a result of oxidative stress, the tyrosine regions of the tau protein are nitrated [ 105 ]. The most common markers used to determine levels of oxidative stress are 8-hydroxy-2’-deoxyguanosine (8-OHdG) and 8-hydroxyguanosine (8-OHG), which are products of oxidation of DNA and RNA bases by hydroxyl radicals.…”

Section: Alzheimer’s Diseasementioning

confidence: 99%

Metabolomic Footprint of Disrupted Energetics and Amino Acid Metabolism in Neurodegenerative Diseases: Perspectives for Early Diagnosis and Monitoring of Therapy

et al. 2023

View full text Add to dashboard Cite

The prevalence of neurodegenerative diseases (NDs) is increasing due to the aging population and improved longevity. They are characterized by a range of pathological hallmarks, including protein aggregation, mitochondrial dysfunction, and oxidative stress. The aim of this review is to summarize the alterations in brain energy and amino acid metabolism in Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). Based on our findings, we proposed a group of selected metabolites related to disturbed energy or mitochondrial metabolism as potential indicators or predictors of disease. We also discussed the hidden challenges of metabolomics studies in NDs and proposed future directions in this field. We concluded that biochemical parameters of brain energy metabolism disruption (obtained with metabolomics) may have potential application as a diagnostic tool for the diagnosis, prediction, and monitoring of the effectiveness of therapies for NDs. However, more studies are needed to determine the sensitivity of the proposed candidates. We suggested that the most valuable biomarkers for NDs studies could be groups of metabolites combined with other neuroimaging or molecular techniques. To attain clinically applicable results, the integration of metabolomics with other “omic” techniques might be required.

show abstract

Section: Alzheimer’s Diseasementioning

confidence: 99%